SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

PEREZ VELA, J.L.  y  SEMICYUC. Grupo de Trabajo de Cuidados Intensivos Cardiológicos y RCP et al. Resumen del documento de consenso «Guías de práctica clínica para el manejo del síndrome de bajo gasto cardiaco en el postoperatorio de cirugía cardiaca». Med. Intensiva [online]. 2012, vol.36, n.4, pp.277-287. ISSN 0210-5691.

    1. Rao V., Ivanov J., Weisel R.D., Ikonomidis J.S., Christakis G.T., David T.E. Predictors of low cardiac output syndrome after coronary artery bypass. J Thorac Cardiovasc Surg. 1996; 112:38-51. [ Links ]

    2. Álvarez Escudero J., Taboada Muñiz M., Rodríguez Forja M.J., Rey Jorge M., Ulloa Iglesias B., Ginesta Galán V. Complicaciones hemodinámicas de la cirugía cardiaca. En: Otero Rufilanchas Belda editors. En: Riesgo y complicaciones en Cirugía Cardiaca. Ed Médica Panamericana SA; 2004. 205-19. [ Links ]

    3. Rudiger A., Businger F., Streit M., Schmid E.R., Maggiorini M., Follath F. Presentation and outcome of critically ill medical and cardiac-surgery patients with acute heart failure. Swiss Med Wkly. 2009; 139:110-6. [ Links ]

    4. Mebazaa A., Pitsis A.A., Rudiger A., Toller W., Longrois D., Ricksten S.E., et al. Practical recommendations on the management of perioperative heart failure in cardiac surgery. Critical Care. 2010; 14:201-14. [ Links ]

    5. Carl M., Alms A., Braun J., Dongas A., Erb J., Goetz A., et al. S3 guidelines for intensive care in cardiac surgery patients: hemodynamic monitoring and cardiocirculary system. Ger Med Sci. 2010; 8:. Doc12. [ Links ]

    6. Atkins D., Best D., Briss P.A., Eccles M., Falck-Ytter Y., Flottorp S., et al, GRADE working Group. Grading quality of evidence and strength of recommendations. BMJ. 2004; 328:1490-8. [ Links ]

    7. [consultado 9 Jun 2010]. [ Links ]

    8. Sakamoto T., Yamada T. Hemodynamic effects of dobutamine in patients following open heart surgery. Circulation. 1977; 55:525-33. [ Links ]

    9. Van Trigt P., Spray T.L., Pasque M.K., Peyton R.B., Pellom G.L., Wechsler A.S. The comparative effects of dopamine and dobutamine on ventricular mechanics after coronary artery bypass grafting: a pressure-dimension analysis. Circulation. 1984; 70:1112-7. [ Links ]

    10. Fowler M.B., Alderman E.L., Oesterle S.N., Derby G., Daughters G.T., Stinson E.B., et al. Dobutamine and dopamine after cardiac surgery: greater augmentation of myocardial blood flow with dobutamine. Circulation. 1984; 70:1103-11. [ Links ]

    11. Costa P., Ottino G.M., Matani A., Pansini S., Canavese C., Passerini G., et al. Low-dose dopamine Turing cardiopulmonary bypass in patients with renal dysfunction. J Cardiothorac Anesth. 1990; 4:469-73. [ Links ]

    12. Boldt J., Kling D., Zickmann B., Dapper F., Hempelmann G. Efficacy of the phosphodiesterase inhibitor enoximone in complicated cardiac surgery. Chest. 1990; 98:53-8. [ Links ]

    13. Schwenzer K.J., Kopel RF. Hemodynamic and metabolic effects of dobutamine in 18 patients after open heart surgery. Crit Care Med. 1990; 18:1107-10. [ Links ]

    14. Royster R.L., Butterworth J.F., Prielipp R.C., Robertie P.G., Kon N.D., Tucker W.Y., et al. A randomized, blinded, placebo-controlled evaluation of calcium chloride and epinephrine for inotropic support after emergence from cardiopulmonary bypass. Anesth Analg. 1992; 74:3-13. [ Links ]

    15. Dupuis J.Y., Bondy R., Cattran C., Nathan H.J., Wynands J.E. Amrinone and dobutamine as primary treatment of low cardiac output syndrome following coronary artery surgery: a comparison of their effects on hemodynamics and outcome. J Cardiothorac Vasc Anesth. 1992; 6:542-53. [ Links ]

    16. Butterworth JF, Zaloga GP, Prielipp RC, Tucker WY, Royster RL. Calcium inhibits the cardiac stimulating properties of dobutamine but not of amrinone. Chest. 1992; 101:174-80. [ Links ]

    17. Ruokonen E., Takala J., Kari A. Regional blood flow and oxygen transport in patients with the low cardiac output syndrome after cardiac surgery. Crit Care Med. 1993; 21:1304-11. [ Links ]

    18. Tarr T.J., Moore N.A., Frazer R.S., Shearer E.S., Desmond MJ. Haemodynamic effects and comparison of enoximone, dobutamine and dopamine following mitral valve surgery. Eur J Anaesthesiol Suppl. 1993; 8:15-24. [ Links ]

    19. Royster R.L., Butterworth J.F., Prielipp R.C., Zaloga G.P., Lawless S.G., Spray B.J., et al. Combined inotropic effects of amrinone and epinephrine after cardiopulmonary bypass in humans. Anesth Analg. 1993; 77:662-72. [ Links ]

    20. Butterworth J.F., Royster R.L., Prielipp R.C., Lawless S.T., Wallenhaupt SL. Amrinone in cardiac surgical patients with left-ventricular dysfunction. Chest. 1993; 104:1660-7. [ Links ]

    21. Günnicker M., Brinkmann M., Donovan T.J., Freund U., Schieffer M., Reidemeister J.C. The efficacy of amrinone or adrenaline on low cardiac output following cardiopulmonary bypass in patients with coronary artery disease undergoing preoperative beta-blockade. Thorac Cardiovasc Surg. 1995; 43:153-60. [ Links ]

    22. Butterworth J.F., Hines R.L., Royster R.L., James R.L. A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. Anesth Analg. 1995; 81:783-92. [ Links ]

    23. Kikura M., Lee M.K., Safon R.A., Bailey J.M., Levy J.H. The effects of milrinone on platelets in patients undergoing cardiac surgery. Anesth Analg. 1995; 81:44-8. [ Links ]

    24. Kikura M., Levy J.H., Michelsen L.G., Shanewise J.S., Bailey J.M., Sadel S.M., et al. The effect of milrinone on hemodynamics and left ventricular function after emergence from cardiopulmonary bypass. Anesth Analg. 1997; 85:16-22. [ Links ]

    25. Rosseell P.M.J., Santman F.W., Bouter H., Dott C.S. Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?. Intensive Care Med. 1997; 23:962-8. [ Links ]

    26. Berendes E., Möllhoff T., Van Aken H., Schmidt C., Erren M., Deng M.C., et al. Effects of dopexamine on creatinine clearance, systemic inflammation, and splanchnic oxygenation in patients undergoing coronary artery bypass grafting. Anesth Analg. 1997; 84:950-7. [ Links ]

    27. Hachenberg T., Möllhoff T., Holst D., Brüssel T. Cardiopulmonary effects of enoximone or dobutamine and nitroglycerin on mitral valve regurgitation and pulmonary venous hypertension. J Cardiothorac Vasc Anesth. 1997; 11:453-7. [ Links ]

    28. Totaro R.J., Raper R.F. Epinephrine-induced lactic acidosis following cardiopulmonary bypass. Crit Care Med. 1997; 25:1693-9. [ Links ]

    29. Jenkins I.R., Dolman J., O'Connor J.P., Ansley D.M. Amrinone versus dobutamine in cardiac surgical patients with severe pulmonary hypertension after cardiopulmonary bypass: a prospective, randomized double-blinded trial. Anaesth Intensive care. 1997; 25:245-9. [ Links ]

    30. Doolan L.A., Jones E.F., Kalman J., Buxton B.F., Tonkin A.M. A placebo-controlled trial verifying the efficacy of milrinone in weaning high-risk patients from cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 1997; 11:37-41. [ Links ]

    31. Lobato E.B., Florete O., Bingham H.L. A single dose of milrinone facilitates separation from cardiopulmonary bypass in patients with pre-existing left ventricular dysfunction. Br J Anaesth. 1998; 81:782-4. [ Links ]

    32. Kikura M., Levy J.H., Bailey , Shanewise J.S., Michelsen L.G., Sadel M. A bolus dose of 1.5mg/kg amrinone effectively improves low cardiac output state following separation from cardiopulmonary bypass in cardiac surgical patients. Acta Anesth Scand. 1998; 42:825-33. [ Links ]

    33. Butterworth J.F., Legault C., Royster R.L., Hammon J.W. Factors that predict the use of positive inotropic drug support after cardiac valve surgery. Anesth Analg. 1998; 86:461-7. [ Links ]

    34. Rathmell J.P., Prielipp R.C., Butterworth J.F., Williams E., Villamaria F., Testa L., et al. A multicenter, randomized, blind comparison of amrinone with milrinone after elective cardiac surgery. Anesth Analg. 1998; 86:683-90. [ Links ]

    35. Lilleberg J., Nieminem M.S., Akkila J., Heikkila L., Kuitunen A., Lehtonen L., et al. Effects of a new calcium sensitizer, levosimendan, on hemodynamics, coronary blood flow and myocardial substrate utilization early after CABG. Eur Heart J. 1998; 19:660-8. [ Links ]

    36. Romson J.L., Leung J.M., Bellows W.H., Bronstein M., Keith F., Moores W., et al. Effects of dobutamine on hemodynamics and left ventricular performance after cardiopulmonary bypass in cardiac surgical patients. Anesthesiology. 1999; 91:1318-28. [ Links ]

    37. Thorén A., Elam M., Ricksten SE.. Differential effects of dopamine, dopexamine, and dobutamine on jejunal mucosal perfusion early after cardiac surgery. Crit Care Med. 2000; 28:2338-43. [ Links ]

    38. Yamada T., Takeda J., Katori N., Tsuzaki K., Ochiai R. Hemodynamic effects of milrinone during weaning from cardiopulmonary bypass: comparison of patients with a low and high prebypass cardiac index. J Cardiothorac Vasc Anesth. 2000; 14:367-73. [ Links ]

    39. Feneck R.O., Sherry K.M., Withington P.S., Oduro-Dominah A., European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. J Cardiothorac Vasc Anesth. 2001; 15:306-15. [ Links ]

    40. Kikura M., Sato S. The efficacy of preemptive milrinone or amrinone therapy in patients undergoing coronary artery bypass grafting. Anesth Analg. 2002; 94:22-30. [ Links ]

    41. Kivikko M., Lehtonen L., Colucci W.S. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 2003; 107:81-6. [ Links ]

    42. Dernellis J., Panaretou M. Effects of levosimendan on restrictive left ventricular filling in severe heart failure: a combined hemodynamic and Doppler echocardiographic study. Chest. 2005; 128:2633-9. [ Links ]

    43. Álvarez J., Bouzada M., Fernández A.L., Caruezo V., Taboada M., Rodríguez J., et al. Comparación de los efectos hemodinámicos del levosimendán con la dobutamina en los pacientes con bajo gasto cardiaco después de cirugía cardiaca. Rev Esp cardiol. 2006; 59:338-45. [ Links ]

    44. Tritapepe L., De Santis V., Vitale D., Santulli M., Morelli A., Nofroni I., et al. Preconditioning effects of levosimendan in coronary artery bypass grafting- a pilot study. Br J Anaesth. 2006; 96:694-700. [ Links ]

    45. Al-Shawaf E., Ayed A., Vislocky I., Radomir B., Dehrab N., Tarazi R. Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery. J Cardiothorac Vasc Anesth. 2006; 20:353-7. [ Links ]

    46. Tasouli A., Papadopoulos K., Antoniou T., Kriaras I., Stavridis G., Degiannis D., et al. Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: importance of early use. Eur J Cardiothorac Surg. 2007; 32:629-33. [ Links ]

    47. De Hert S.G., Lorsomradee S., Cromheecke S., Van der Linden P.J. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg. 2007; 104:766-73. [ Links ]

    48. Heringlake M., Wernerus M., Grünefeld J., Klaus S., Heinze H., Bechtel M., et al. The metabolic and renal effects of adrenaline and milrinone in patients with myocardial dysfunction after coronary artery bypass grafting. Crit Care. 2007; 11:R51. [ Links ]

    49. De Hert S.G., Lorsomradee S., vanden Eede H., Cromheecke S., Van der Linden PJ. A randomized trial evaluating different modalities of levosimendan administration in cardiac surgery patients with myocardial dysfunction. J Cardiothorac Vasc Anest. 2008; 22:699-705. [ Links ]

    50. El Mokhtari N.E., Arlt A., Meissner A., Lins M. Inotropic therapy for cardiac low output syndrome: comparison of hemodynamic effects of dopamine/dobutamine versus dopamine/dopexamine. Eur J Med Res. 2008; 13:459-63. [ Links ]

    51. Järvelä K., Maaranen P., Sisto T., Ruokonen E. Levosimendan in aortic valve surgery: cardiac performance and recovery. J Cardiothorac Vasc Anesth. 2008; 22:693-8. [ Links ]

    52. Levin R.L., Degrange M.A., Porcile R., Salvagio F., Blanco N., Botbol A.L., et al. Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el síndrome de bajo gasto cardiaco postoperatorio. Rev Esp Cardiol. 2008; 61:471-9. [ Links ]

    53. Tritapepe L., De Santis V., Vitale D., Guarracino F., Pellegrini F., Pietropaoli P., et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth. 2009; 102:198-204. [ Links ]

    54. Zangrillo A., Biondi-Zoccai G., Mizzi A., Bruno G., Bignami E., Gerli C., et al. Levosimendan reduces cardiac troponin release after cardiac surgery: a meta-analysis of randomized controlled studies. J Cardiothorac Vasc Anesth. 2009; 23:474-8. [ Links ]

    55. Eriksson H.I., Jalonen J.R., Heikkinen L.O., Kivikko M., Laine M., Leino K.A., et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Ann Thorac Surg. 2009; 87:448-54. [ Links ]

    56. Noto A., Lentini S., Versaci A., Giardina M., Risitano D.C., Messina R., et al. A retrospective analysis of terlipressin in bolus for the management of refractory vasoplegic hypotension after cardiac surgery. Interact CardioVasc Thorac Surg. 2009; 9:588-92. [ Links ]

    57. Landoni G., Mizzi A., Biondi-Zoccai G., Bruno G., Bignami E., Corno L., et al. Reducing mortality in cardiac surgery with levosimendan: a meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth. 2010; 24:51-7. [ Links ]

    58. Ranucci M., De Benedetti D., Bianchini C., Castelvecchio S., Ballotta A., Frigiola A., et al. Effects of fenoldopam infusion in complex cardiac surgical operations: a prospective, randomized, double-blind, placebo-controlled study. Minerva Anestesiol. 2010; 76:249-59. [ Links ]

    59. Loeb H.S., Winslow E.B.J., Rahimtoola S.H., Rosen K.M., Gunnar R.M. Acute hemodynamic effects of dopamine in patients with shock. Circulation. 1971; 44:163-73. [ Links ]

    60. Leier C.V, Webel J., Bush CA. The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure. Circulation. 1977; 56:468-72. [ Links ]

    61. Loeb H.S., Bredakis J., Gunnar RM. Superiority of dobutamine over dopamine for augmentation of cardiac output in patients with chronic low output cardiac failure. Circulation. 1977; 55:375-81. [ Links ]

    62. Baim D.S., McDowell A.V., Cherniles J., Monrad E.S., Parker J.A., Edelson J., et al. Evaluation of a new bipyridine inotropic agent-milrinone-in patients with severe congestive heart failure. N Engl J Med. 1983; 309:748-56. [ Links ]

    63. Packer M., Medina N., Yushak M. Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. Circulation. 1984; 70:1038-47. [ Links ]

    64. Anderson J.L., Baim D.S., Fein S.A., Goldstein R.A., Lejemtel T.H., Likoff M.J. Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patiens with severe congestive heart failure: a multicenter study. JACC. 1987; 9:711-22. [ Links ]

    65. Leier C.V., Lima J.J., Meiler S.E., Unverferth D.V. Central and regional hemodynamic effects of oral enoximone in congestive heart failure: a double-blind, placebo-controlled study. Am Heart J. 1988; 115:1051-9. [ Links ]

    66. DiBianco R., Shabetai R., Kostuk W., Moran J., Schlant R.C., Wright R. A comparison of oral milrinone digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med. 1989; 320:677-83. [ Links ]

    67. Urestky B.F., Jessup M., Konstam M.A., Dec G.W., Leier CV., Benotti J., et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Circulation. 1990; 82:774-80. [ Links ]

    68. Packer M., Carver J.R., Rodeheffer R.J., Ivanhoe R.J., DiBianco R., Zeldis S.M., et al, for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991; 325:1468-75. [ Links ]

    69. Nieminen M.S., Akkila J., Hasenfuss G., Kleber F.X., Lehtonen L.A., Mitrovic V., et al. Hemodynamic and neurohumoral effects of continuous infusión of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000; 36:1903-12. [ Links ]

    70. Slawsky M.T., Colucci W.S., Gottlieb S.S., Greenberg B.H., Haeusslein E., Hare J., et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation. 2000; 102:2222-7. [ Links ]

    71. Yamani M.H., Haji S.A., Starling R.C., Kelly L., Albert N., Knack D.L., et al. Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: hemodynamic efficacy, clinical outcome, and economic impact. Am Heart J. 2001; 142:998-1002. [ Links ]

    72. Thackray S., Easthaugh J., Freemantle N., Cleland J.G. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail. 2002; 4:515-29. [ Links ]

    73. Follath F., Cleland J.F.G., Just H., Papp J.G.Y., Peuhkurinen K., Harjola V.P., et al. Efficacy and safety of intravenous levosimendan compared with dobutamina in severe low-output heart failure (the LIDO study): a randomized double blind trial. Lancet. 2002; 360:196-202. [ Links ]

    74. Cuffe M.S., Califf R.M., Adams K.F., Benza R., Bourge R., Colucci W.S., et al, Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure. A randomized controlled trial. JAMA. 2002; 287:1541-7. [ Links ]

    75. Moiseyev V.S., Pöder P., Andrejevs N., Ruda M.Y., Golikov A.P., Lazebnik L.B., et al, on behalf of RUSSLAN Study Investigators. Eur Heart J. 2002; 23:1422-32. [ Links ]

    76. Mebazaa A., Nieminen M.S., Packer M., Cohen-Solal A., Kleber F.X., Pocock S.J., et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure. The SURVIVE randomized trial. JAMA. 2007; 297:1883-91. [ Links ]

    77. Fuhrmann J.T., Schmeisser A., Schulze M.R., Wunderlich C., Schoen S.P., Rauwolf T., et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med. 2008; 36:2257-66. [ Links ]

    78. Mebazaa A., Nieminen M., Filippatos G.S., Cleland J.G., Salon J.E., Yhakkar R., et al. Levosimendan vs dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart fail. 2009; 11:304-11. [ Links ]

    79. Russ M.A., Prondzinsky R., Carter J.M., Schlitt A., Ebelt H., Schmidt H., et al. Right ventricular function in myocardial infarction complicated by cardiogenic shock: Improvement with levosimendan. Crit Care Med. 2009; 37:3017-23. [ Links ]

    80. De Backer D., Biston P., Devriendt J., Madl C., Chochrad D., Aldecoa C., et al, SOAP II investigators. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010; 362:779-89. [ Links ]

    81. Nieminen M.S., Böhm M., Cowie M.R., Drexler H., Filippatos G.S., Jondeau G., et al, ESC Committee for Practice Guideline. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005; 26:384-416. [ Links ]

    82. Dickstein K., Cohen-Solal A., Filippatos G., McMurray J,J., Ponikowski P., Poole-Wilson P.A., et al, ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008; 29:2388-442. [ Links ]

    83. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009; 119:e391-479. [ Links ]

    84. Boeken U., Feindt P., Litmathe J., Kart M., Gams E. Intraaortic Balloon Pumping in Patients with right ventricular insufficiency after cardiac surgery: Parameters to predict failure of IABP support. Thorac Cardiovasc Surg. 2009; 57:324-8. [ Links ]

    85. Liakopoulos Oj ., Ho J.K., Yezbick A.B., Sanchez E., Singh V., Mahajan A. Right ventricular failure resulting from pressure overload: Role of intra-aortic balloon counterpulsation and vasopressor therapy. J Surg Res. 2009; 1-9. [ Links ]

    86. Lombard F.W., Grichnik K.P. Update on management strategies for separation from cardiopulmonary bypass. Curr Opin Anaesthesiol. 2011; 24:49-57. [ Links ]

    87. Haussmann H., Potapov E.V., Koster A., Krabatsch T., Stein J., Meter R., et al. Prognosis alter the implantation of a Intra-Aortic Balloon Pump in cardiac surgery calculated with a new score. Circulation. 2002; 106(suppl 1):. 203-I-206. [ Links ]

    88. Prondzinsky R., Lemm H., Swyter M., Wegener N., Unverzagt S., Justin M., et al. Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction síndrome. Crit Care Med. 2010; 38. [ Links ]